NEW YORK (Reuters Health) - The use of beta2-agonists and inhaled corticosteroid

s for asthma during pregnancy is associated with an increased risk of a few spec
ific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove

rall risk of congenital anomalies, and earlier studies suggested an increased ri

sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medicationsNEW YORK (Reuters Health) - The use of beta2-agonists and
inhaled corticosteroids for asthma during pregnancy is associated with an increa
sed risk of a few specific congenital anomalies, according to a European study.
Maternal asthma and its exacerbations are associated with an increase in the ove
rall risk of congenital anomalies, and earlier studies suggested an increased ri
sk of certain anomalies after first-trimester exposure to asthma medications.
Dr. Ester Garne from Hospital Lillebaelt Kolding in Kolding, Denmark, and collea
gues used data from 13 European population-based congenital anomaly registries t
o investigate the risk of specific congenital anomalies in relation to specific
antiasthma medications